Asta Medica, Aktiengesellschaft

Almirall, S.a.

Meda Pharma Gmbh & Co. Kg

Sofotec Gmbh & Co. Kg

Viatris Gmbh & Co Kg

Joachim Goede

Karl-Heinz Lange

Helmut Hettche

Anne Haaije De Boer

Martin Herder

Wolfgang Gottenauer

Andre Narodylo

Jurgen Engel

Istvan Szelenyi

Joachim Maus

Coenraad Lerk

Meike Eilbracht

Klaus Huthmacher

Herbert Klenk

J&uuml;rgen Engel

Horst Bethge

Thomas Beisswenger

Henderik Willem Frijlink

Frank Hubner

Roland Moller

Michael Lobisch

Ingo Mett

Peter Jurgen Cnota

Helmut Momberger

Paul Hagedoorn

Peter Jürgen Cnota

Doetie Gjaltema

Peter Juergen Cnota

The present invention describes the combination of topically inhaled medicinal formulations comprising an anticholinergic component and a glucocorticosteroid component and its use in the symptomatic and prophylactic treatment of diseases of the respiratory tract, especially with an obstructive component or underlying inflammation like asthma and chronic obstructive pulmonary disease (COPD). It further comprises the presentation of this combination in a locally applied (inhaled) formulation and application in an inhalation device for instance in the NOVOLIZER&#xae;.

Methods of treating underlying inflammation from COPD or asthma

In order to improve the administration of powdered pharmaceuticals, the invention proposes a storage system for powdered pharmaceuticals, in particular for use or integration in a powder inhaler, for receiving a multiplicity of doses of at least one medically active substance, with at least two storage spaces () which are separate from each other and are each intended to hold a multiplicity of doses of a medically active substance, and the invention also proposes an inhaler for powdered pharmaceuticals, the inhaler comprising such a pharmaceutical powder cartridge system () as an integral part or as an exchangeable part.

Storage system for powdered pharmaceuticals, and inhaler equipped with this system

Storage system for powdered pharmaceuticals and inhaler equipped with this system

In order to improve the security and reliability of administration of powdered pharmaceuticals through dry powder inhalers, the invention proposes an inhaler () for powdered medicaments, comprising an activating device () for manual engagement by the patient for repeatedly metering a dose of medicament to be administered to the patient, and further comprising an advancing mechanism () for advancing a counter or indexing means () each time the activating device () has been engaged by the patient so that a dose of medicament has been released for administration to the patient, wherein the counter or indexing means () comprises an index (), the index () being detectable by a detection means () of the inhaler, and the detection means () being coupled to a locking mechanism (), the locking mechanism () blocking the activating device () and/or any transportation mechanism () of the inhaler () delayed by a predetermined number of metering cycles since detection of the index (), and a cartridge ().

Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler

The present invention describes a combination of an anticholinergic, such as R,R-glycopyrrolate, and a &#x3b2; mimetic, such as tormoterol, for the treatment of respiratory diseases including airway inflammation or obstruction such as chronic obstructive pulmonary disease (COPD) and asthma.

Combination of anticholineric and &#x3b2; mimetics for the treatment of respiratory diseases

To improve administration of powdered pharmaceuticals, a pharmaceutical powder cartridge () for powder inhalers for holding a pharmaceutical depot for a large number of pharmaceutical powder doses is proposed, having at least one storage space () and an integrated metering device, said integrated metering device comprising at least one metering slide () which can be moved approximately transversely in a metering slide channel () at least from a filling position to an emptying position, approximately transversely with respect to the direction of flow of the pharmaceutical powder out from the at least one storage space (), said metering slide channel () with the at least one metering slide () being sealed off from the environment at least in the filling position of the metering slide (), and also further measures and a corresponding inhaler.

Pharmaceutical powder cartridge, and inhaler equipped with same

A cartridge for powdered pharmaceuticals. At least two storage spaces are provided which are separate from each other and which are each intended to hold a multiplicity of doses of a medically active substance. The storage spaces are individual cartridges which may be lockingly coupled together to form a single cartridge. Each individual cartridge has a metering cavity.

A disperser for dry powders which can be used with different dose systems, dose weights ranging from 2 to 25 mg and different types of powder formulation. In one embodiment, the disperser acts both as a de-agglomeration (disintegration; aerosolization) means and as an air classifier for especially adhesive mixtures. Only fine drug particles are emitted whereas the larger agglomerates and carrier crystals are retained by the disperser. Another embodiment enables time controlled release of carrier crystals in these mixtures. Yet another embodiment has optimized performance with spherical pellets, containing no carrier crystals. Other possible embodiments of the invention make it possible to control the total inhaler resistance and the powder deposition in the upper respiratory tract by means of the addition of a so-called sheath flow of clean air. Modifications also enable carrier retainment in the mouthpiece and elimination of the tangential flow component of the discharge cloud.

Powder formulation disintegrating system and method for dry powder inhalers

Pharmaceutical dosage units containing flupirtine or a pharmaceutically acceptable salt of flupirtine with controlled release of active substance using a delayed-action or controlled-release component. There are 0.001 to 20 parts delayed-action component for each part by weight flupirtine (calculated as the base) and the release rate of flupirtine is between 5 and 300 mg per hour. In some cases, the dosage units may also contain a rapidly releasing component of flupirtine or of one of its salts. The dosage units reduce the sedative effect of flupirtine.

Oral forms of administration containing solid flupirtine with controlled release of active substance

Pharmaceutical powder cartridge for powder inhalers for receiving a medicament depot for a large number of pharmaceutical powder doses, having an integrated metering device which comprises at least one metering cavity for receiving a predetermined quantity of a pharmaceutical powder, the integrated metering device being capable of being moved at least out of a filling position into an emptying position approximately transversely with respect to the flow direction of the pharmaceutical powder, and an inhaler for powdered medicaments, in which inhaler the medicament can be received by a patient by means of an air stream and which has a receptacle for such a pharmaceutical powder cartridge.

Inhaler for powdered medicaments

The present invention relates to an inhaler for administering medicaments (38) from blister packs (5), which has a housing with a mouthpiece (1) on one side, an air inlet opening (32) on the opposite side and, between them on the inside, a duct (7) which connects the mouthpiece (1) and the air inlet opening (32), it being possible for at least one blister strip (5) to be inserted into the housing so that the covering foil (35) of the inserted blister strip (5) adjoins the duct (7). The housing has means for pressing out the individual cavities (31) of the blister strip (5), which means contain at least one plunger (10) with a curved plunger surface, which corresponds to the shape of the blister cavities (31), for engagement on the blister cavity.

Inhaler for administering medicaments from blister packs

Pharmaceutical powder cartridge with integrated metering device and

A solid medicinal form having an active substance content of over 45 weight % and a process for its preparation by granulating with large amounts of water, drying and optionally conventional tableting and/or pelleting.

Tablets, granulates and pellets with a high active substance content for

RS-thioctic acid with a novel morphology which is obtained by a recrystallization process.

Growing community of inventors

Hanau, Germany

Joachim Goede